|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marshall HM, Leong SC, Bowman RV, et al:
The science behind the 7th edition Tumour, Node, Metastasis staging
system for lung cancer. Respirology. 17:247–260. 2012. View Article : Google Scholar
|
|
3
|
Morgensztern D, Waqar S, Subramanian J, et
al: Prognostic impact of malignant pleural effusion at presentation
in patients with metastatic non-small-cell lung cancer. J Thorac
Oncol. 7:1485–1489. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zahreddine H and Borden LB: Mechanisms and
insights into drug resistance in cancer. Front Pharmacol. 4:282013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Suh DH, Kim MK, Kim HS, Chung HH and Song
YS: Epigenetic therapies as a promising strategy for overcoming
chemoresistance in epithelial ovarian cancer. J Cancer Prev.
18:227–234. 2013. View Article : Google Scholar
|
|
6
|
Zhang L, Yang H and Xu J: Gene expression
significance in personalized medicine of non-small-cell lung cancer
and gene expression analyzing platforms. Curr Drug Metab.
12:455–459. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sancar A and Reardon JT: Nucleotide
excision repair in E. coli and man. Adv Protein Chem. 69:43–71.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Van Den Broeck A, Nissou D, Brambilla E,
et al: Activation of a Tip60/E2F1/ERCC1 network in human lung
adenocarcinoma cells exposed to cisplatin. Carcinogenesis.
33:320–325. 2012. View Article : Google Scholar
|
|
9
|
Olaussen KA, Dunant A, Fouret P, et al:
DNA repair by ERCC1 in non-small-cell lung cancer and
cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xianjun F, Xiu-guang Q, Li Z, et al: ERCC1
and BRCA1 mRNA expression predicts the clinical outcome of
non-small cell lung cancer receiving platinum-based chemotherapy.
Pak J Med Sci. 30:488–492. 2014.
|
|
11
|
Gangjee A, Yu J, McGuire JJ, et al:
Design, synthesis, and X-ray crystal structure of a potent dual
inhibitor of thymidylate synthase and dihydrofolate reductase as an
antitumor agent. J Med Chem. 43:3837–3851. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sigmond J, Backus HH, Wouters D, et al:
Induction of resistance to the multitargeted antifolate Pemetrexed
(ALIMTA) in WiDr human colon cancer cells is associated with
thymidylate synthase overexpression. Biochem Pharmacol. 66:431–438.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang T, Chuan Pan C, Rui Yu J, et al:
Association between TYMS expression and efficacy of
pemetrexed-based chemotherapy in advanced non-small cell lung
cancer: a meta-analysis. PLoS one. 8:e742842013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rosell R, Cobo M, Isla D, et al:
Pharmacogenomics and gemcitabine. Ann Oncol. 17(Suppl 5): 13–16.
2006. View Article : Google Scholar
|
|
15
|
Vilmar AC, Santoni-Rugiu E and Sorensen
JB: Predictive impact of RRM1 protein expression on vinorelbine
efficacy in NSCLC patients randomly assigned in a chemotherapy
phase III trial. Ann Oncol. 24:309–314. 2013. View Article : Google Scholar
|
|
16
|
Katsetos CD, Herman MM and Mörk SJ: Class
III beta-tubulin in human development and cancer. Cell Motil
Cytoskeleton. 55:77–96. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
McCarroll JA, Gan PP, Liu M and Kavallaris
M: betaIII-tubulin is a multifunctional protein involved in drug
sensitivity and tumorigenesis in non-small cell lung cancer. Cancer
Res. 70:4995–5003. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim JH and Adelstein RS: LPA(1)-induced
migration requires nonmuscle myosin II light chain phosphorylation
in breast cancer cells. J Cell Physiol. 226:2881–2893. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Merx MW, Flögel U, Stumpe T, et al:
Myoglobin facilitates oxygen diffusion. FASEB J. 15:1077–1079.
2001.PubMed/NCBI
|
|
20
|
Flonta SM, Arena S, Pisacane A, et al:
Expression and functional regulation of myoglobin in epithelial
cancers. Am J Pathol. 175:201–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jin W, Liu Y, Chen L, et al: Involvement
of MyoD and c-myb in regulation of basal and estrogen-induced
transcription activity of the BRCA1 gene. Breast Cancer Res Treat.
125:699–713. 2011. View Article : Google Scholar
|
|
22
|
Soleimani VD, Yin H, Jahani-Asl A, et al:
Snail regulates MyoD binding-site occupancy to direct enhancer
switching and differentiation-specific transcription in myogenesis.
Mol Cell. 47:457–468. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Polo V and Besse B: Maintenance strategies
in stage IV non-small-cell lung cancer (NSCLC): in which patients,
with which drugs? Ann Oncol. 25:1283–1293. 2014. View Article : Google Scholar
|
|
24
|
Hildebrandt MA, Gu J and Wu X:
Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert
Opin Drug Metab Toxicol. 5:745–755. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ota S, Ishii G, Goto K, et al:
Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen
predicts survival in advanced non-small-cell lung cancer treated
with cisplatin-based chemotherapy. Lung Cancer. 64:98–104. 2009.
View Article : Google Scholar
|
|
26
|
Das M, Riess JW, Frankel P, et al: ERCC1
expression in circulating tumor cells (CTCs) using a novel
detection platform correlates with progression-free survival (PFS)
in patients with metastatic non-small-cell lung cancer (NSCLC)
receiving platinum chemotherapy. Lung Cancer. 77:421–426. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao Z, Han B, Shen J, et al: ERCC1 protein
as a guide for individualized therapy of late-stage advanced
non-small cell lung cancer. Exp Ther Med. 2:811–815. 2011.
|
|
28
|
Shimizu T, Nakanishi Y, Nakagawa Y, et al:
Association between expression of thymidylate synthase,
dihydrofolate reductase, and glycinamide ribonucleotide
formyltransferase and efficacy of pemetrexed in advanced non-small
cell lung cancer. Anticancer Res. 32:4589–4596. 2012.PubMed/NCBI
|
|
29
|
Dong X, Hao Y, Wei Y, et al: Response to
first-line chemotherapy in patients with non-small cell lung cancer
according to RRM1 expression. PLoS One. 9:e923202014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gong W, Zhang X, Wu J, et al: RRM1
expression and clinical outcome of gemcitabine-containing
chemotherapy for advanced non-small-cell lung cancer: a
meta-analysis. Lung Cancer. 75:374–380. 2012. View Article : Google Scholar
|
|
31
|
Dumontet C, Isaac S, Souquet PJ, et al:
Expression of class III beta tubulin in non-small cell lung cancer
is correlated with resistance to taxane chemotherapy. Bull Cancer.
92:E25–E30. 2005.PubMed/NCBI
|
|
32
|
Sève P, Isaac S, Trédan O, et al:
Expression of class III β-tubulin is predictive of patient outcome
in patients with non-small cell lung cancer receiving
vinorelbine-based chemotherapy. Clin Cancer Res. 11:5481–5486.
2005. View Article : Google Scholar
|
|
33
|
Ferrandina G, Zannoni GF, Martinelli E, et
al: Class III beta-tubulin overexpression is a marker of poor
clinical outcome in advanced ovarian cancer patients. Clin Cancer
Res. 12:2774–2779. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tommasi S, Mangia A, Lacalamita R, et al:
Cytoskeleton and paclitaxel sensitivity in breast cancer: the role
of beta-tubulins. Int J Cancer. 120:2078–2085. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Portyanko A, Kovalev P, Gorgun J and
Cherstvoy E: beta(III)-tubulin at the invasive margin of colorectal
cancer: possible link to invasion. Virchows Arch. 454:541–548.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Katsetos CD and Dráber P: Tubulins as
therapeutic targets in cancer: from bench to bedside. Curr Pharm
Des. 18:2778–2792. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Maus MK, Mack PC, Astrow SH, et al:
Histology-related associations of ERCC1, RRM1, and TS biomarkers in
patients with non small-cell lung cancer: implications for therapy.
J Thoracic Oncol. 8:582–586. 2013.
|
|
38
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Z, Li Y, Kong D, et al: Acquisition
of epithelial-mesenchymal transition phenotype of
gemcitabine-resistant pancreatic cancer cells is linked with
activation of the notch signaling pathway. Cancer Res.
69:2400–2407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang AD, Fan F, Camp ER, et al: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kajiyama H, Shibata K, Terauchi M, et al:
Chemoresistance to paclitaxel induces epithelial-mesenchymal
transition and enhances metastatic potential for epithelial ovarian
carcinoma cells. Int J Oncol. 31:277–283. 2007.PubMed/NCBI
|
|
42
|
Hsu DS, Lan HY, Huang CH, et al:
Regulation of excision repair cross-complementation group 1 by
Snail contributes to cisplatin resistance in head and neck cancer.
Clin Cancer Res. 16:4561–4571. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kocaefe C, Balci D, Hayta BB and Can A:
Reprogramming of human umbilical cord stromal mesenchymal stem
cells for myogenic differentiation and muscle repair. Stem Cell
Rev. 6:512–522. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Giarnieri E, De Vitis C, Noto A, et al:
EMT markers in lung adenocarcinoma pleural effusion spheroid cells.
J Cell Physiol. 228:1720–1726. 2013. View Article : Google Scholar
|
|
45
|
Oleksiewicz U, Daskoulidou N, Liloglou T,
et al: Neuroglobin and myoglobin in non-small cell lung cancer:
expression, regulation and prognosis. Lung Cancer. 74:411–418.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xiong D, Ye YL, Chen MK, et al: Non-muscle
myosin II is an independent predictor of overall survival for
cystectomy candidates with early-stage bladder cancer. Oncol Rep.
28:1625–1632. 2012.PubMed/NCBI
|
